Edwards TAVR halves heart‑failure hospitalizations in moderate aortic stenosis trial
Edwards Lifesciences reported that its transcatheter aortic valve replacement (TAVR) cut heart‑failure hospitalizations by more than 50% versus clinical monitoring in the Phase 3 PROGRESS trial. The study enrolled 744 patients with moderate aortic stenosis and at‑risk features across 74 sites. At two years, the combined rate of death or heart‑failure events was 33% lower for TAVR (16.7%) than for surveillance (23.9%). The procedure also showed a favorable safety profile and improved quality‑of‑life scores.
Why it matters
The company says the results could broaden the use of TAVR into the moderate‑stenosis market, potentially increasing future product demand. The stock rose 1.36% after the announcement, reflecting investor optimism.
Key facts
- 1The PROGRESS trial randomized 744 patients with moderate aortic stenosis to TAVR or clinical surveillance. rttnews.com
- 2Heart‑failure events occurred in 10.8% of TAVR patients versus 19.0% of those under surveillance. rttnews.com
- 3Heart‑failure hospitalizations were 7.4% for TAVR and 14.9% for surveillance. rttnews.com
- 4The composite endpoint of death or heart‑failure events was 16.7% with TAVR and 23.9% with surveillance, a 33% relative reduction. rttnews.com
- 5No deaths or disabling strokes were reported within 30 days after TAVR. rttnews.com
- 6Patients receiving TAVR improved their Kansas City Cardiomyopathy Questionnaire score by 15.5 points at 30 days. rttnews.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.